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Summary Background Psoriasis is a chronic and recurrent inflammatory skin disease. The inflammatory
response represents a fundamental ability of the organism to protect itself from infectious agents
and from injury.
Objectives To evaluate the inflammatory response in mild and in severe psoriasis, to evaluate the
endogenous systems counterbalancing the deleterious effects of the inflammation products, and to
establish values of prognostic significance.
Methods The study was performed in a control group (n ¼ 40) and in 60 patients with psoriasis
vulgaris, half presenting with mild psoriasis, and the other half with severe psoriasis. We evaluated
total and differential leucocyte count; elastase, lactoferrin and lipid peroxidation as markers of
neutrophil activation; total plasma antioxidant capacity (TAS), transferrin, ceruloplasmin,
a1-antitrypsin and a2-macroglobulin as markers of the endogenous antioxidant and antiprotease
systems; and fibrinogen, erythrocyte sedimentation rate, C-reactive protein (CRP), haptoglobin, C3
and C4 complement proteins as markers of inflammation.
Results Our data suggested that psoriasis is an inflammatory condition in which neutrophils seem
to play a crucial role by contributing to the development of oxidative and proteolytic stress. The
worsening of the disease seemed to be linked to the enhancement of the inflammatory response and
of the imbalance between neutrophil activation products and their inhibitors.
Conclusions We propose values for elastase, CRP, elastase ⁄ a2-macroglobulin, elastase ⁄ a1-anti-
trypsin, thiobarbituric acid ⁄ TAS and elastase ⁄ neutrophil ratios with prognostic significance for the
worsening of psoriasis.
Key words: C-reactive protein, inflammation, neutrophil activation, neutrophilic elastase, oxidative
stress, psoriasis activity
The inflammatory response represents a fundamental
ability of the organism to protect itself against exposure
to infectious agents and to injury.1 It occurs in vascular
tissue and involves complex interactions between blood
cells, plasma mediator systems and the microvascula-
ture. An inflammatory response usually includes local
haemodynamic changes, alterations in microvascular
permeability and a series of cellular events leading to
accumulation of leucocytes and to their activation.
Psoriasis is known as a chronic and recurrent
inflammatory skin disease, and its worsening has been
linked with oxidative stress.2–4 As any inflammatory
disease, psoriasis often presents a rise in white blood
cells (WBCs), namely in neutrophils. Clinically active
psoriasis lesions show infiltration of WBCs, mainly of
neutrophils, and several studies report high levels of
neutrophil activation products in psoriatic lesions5,6
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and in the peripheral blood of these patients.7 The
activation of neutrophils triggers a set of functional and
metabolic responses, including degranulation, enzyme
release and generation of reactive oxygen species
(ROS).8
ROS have been shown to mediate inflammatory
processes and to be involved in oxidative reactions such
as lipid peroxidation and protein oxidation.9,10 They
may greatly amplify the inflammatory response, but
they may also contribute to tissue damage. To counter-
balance the destructive effects of these oxidants there are
endogenous antioxidant systems, such as the antioxid-
ant enzymes superoxide dismutase, catalase and gluta-
thione peroxidase, promoting the detoxification of
ROS;11 the proteins ceruloplasmin and transferrin, by
linking iron, avoid the development of the Fenton
reaction. This reaction appears to be an important
mechanism for generation of the hydroxyl radical, the
more deleterious oxygen metabolite, from hydrogen
peroxide in the presence of free iron and reducing
agents, namely superoxide, ascorbate and lactate.8,12
The degranulation of activated neutrophils appears
to be important in the inflammatory response and in
tissue damage. For instance, lactoferrin released by the
specific neutrophil granules13 seems to promote neu-
trophil–endothelial cell adhesion and, as a source of
iron, it may also promote the Fenton reaction. Neutral
proteases released by the azurophilic granules of the
activated neutrophils,13 such as elastase, mediate tissue
damage by degradation of matrix proteins. Again, to
limit the deleterious effects of these granular proteases
there are endogenous antiprotease systems.14,15 The
most important antiproteases are a1-antitrypsin and
a2-macroglobulin, which are both synthesized and
secreted in larger quantity when triggered by an
inflammatory process.
The aim of this study was to evaluate the extent of
the inflammatory response in mild and severe psoriasis,
and to evaluate the balance between the products of
the inflammatory response and the endogenous sys-
tems counterbalancing their deleterious effects. We
believe that if the balance between the two systems is
broken, it would lead to enhanced tissue damage and
inflammation, with worsening of psoriasis. Moreover,
by comparing the inflammatory response in mild and
severe psoriasis, we will search for markers of worsen-
ing of the disease.
We studied a control group and a group of patients
with psoriasis vulgaris, half presenting with mild
psoriasis and the other half with severe psoriasis.
Besides total and differential WBC count, we evaluated
plasma levels of elastase and lactoferrin, as traducers of
WBC degranulation and activation. As this activation
is also linked to the generation of ROS, we evaluated
plasma lipid peroxidation as an indirect marker of their
production. To study the capacity of the endogenous
antioxidant systems, total plasma antioxidant capacity,
as well as plasma levels of ceruloplasmin and transfer-
rin, were evaluated. The endogenous antiprotease
system was evaluated by measuring the plasma levels
of a1-antitrypsin and a2-macroglobulin. Fibrinogen,
erythrocyte sedimentation rate (ESR), C-reactive pro-
tein (CRP), haptoglobin, and C3 and C4 complement
proteins were evaluated as markers of inflammation.
Materials and methods
Subjects
The protocol used was approved by the Committee on
Ethics of the University Hospital of Coimbra and all the
patients and controls gave informed consent. As controls,
we studied 40 apparently healthy adults [55% men and
45% women, mean ± SD age 47 ± 13 years, body mass
index (BMI) 24Æ4 ± 1Æ8], with no history of any skin
disease, and presenting with normal haematological and
biochemical values. The selected patients consisted of 60
adults (56% men and 43% women, mean ± SD age
46 ± 12 years, BMI 24Æ7 ± 3Æ1), 30 of them presenting
with mild psoriasis vulgaris (53% men and 46% women,
mean ± SD age 47 ± 13 years, BMI 24Æ2 ± 3Æ6), and
the other 30 presenting with severe psoriasis vulgaris
(60% men and 40% women, mean ± SD age 46 ± 11
years, BMI 25Æ2 ± 2Æ5). The disease was diagnosed from
0Æ5 to 50 years before this study.
We performed a clinical study and blood analysis of
the patients and controls. Individuals presenting defi-
ciencies in erythropoietic nutrients or with other
associated diseases, namely diabetes mellitus, cardio-
vascular, liver or kidney diseases, were excluded from
the study. Individuals with other skin diseases and
alcoholics were also excluded.
Psoriasis was graded according to the Psoriasis Area
and Severity Index (PASI) presenting at the time of blood
collection.16 Half of the patients had severe psoriasis or
active psoriasis (AP; PASI > 3), and the other half had
mild psoriasis or inactive psoriasis (IP; PASI < 3).
To assess the changes imposed by psoriasis per se,
none of the patients had received any systemic or local
steroid medication or any phototherapy treatment for
at least 1 month prior to blood collection. In addition,
the controls, as well as the patients, were not receiving
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any kind of medication, namely antioxidants, vitamins
or anti-inflammatories.
Collection and preparation of blood samples
Blood was collected from the subjects, fasted for 12 h,
with and without anticoagulant, in order to obtain
whole blood, plasma and serum. Sodium citrate and
ethylenediamine tetraacetic acid (EDTA) were used as
anticoagulants. The first was used to collect blood
samples for the evaluation of plasma fibrinogen and
ESR. For the other evaluations in plasma and in whole
blood, EDTA was used as anticoagulant. None of the
samples was icteric or haemolysed.
Assays
Total and differential leucocyte count. Whole blood was
used for these evaluations. An automatic blood cell
counter was used (Autocounter AC 970) to measure
the total and differential WBC count.
Oxidative stress. As an indirect marker of oxygen
metabolite production we evaluated plasma lipid per-
oxidation by measuring the thiobarbituric acid (TBA)
reactivity (TBA assay).17 Total plasma antioxidant
capacity was evaluated by a colorimetric assay (TAS;
Randox Laboratories, Crumlin, U.K.).
Serum levels of transferrin and ceruloplasmin were
evaluated by nephelometry. The levels of the immuno-
complexes formed with the specific antibodies (N Anti-
serum to human transferrin, ceruloplasmin and
haptoglobin; Dade Behring) were detected by using a
nephelometer (BN II; Dade Behring, Marburg, Germany).
Products of neutrophil degranulation. Plasma concen-
trations of polymorphonuclear elastase and lactoferrin
were evaluated by enzyme immunoassays (PMN Elastase
IMAC immunoassay; Merck, Darmstadt, Germany;
Bioxytech lactof enzyme immunoassay, Oxis Interna-
tional, Portland, O.R., U.S.A., respectively).
Markers of inflammation. To measure ESR according
to the Westergren method,18 whole blood was used.
Serum CRP and haptoglobin were evaluated by
nephelometry (N High sensitivity CRP; N Antiserum to
human transferrin, ceruloplasmin and haptoglobin;
Dade Behring).
To evaluate the plasma levels of fibrinogen we used a
turbidimetric assay (Fibrinogen O; DiaMed, Morat,
Switzerland).
The serum levels of complement proteins C3 and C4
were evaluated by nephelometry (Antiserum to human
complement factor C3 and C4; Dade Behring).
Endogenous antiproteases. The plasma levels of
the endogenous antiproteases a1-antitrypsin and
a2-macroglobulin were evaluated by nephelometry (N
Antiserum to human a1-antitrypsin and a2-macro-
globulin; Dade Behring).
Statistical analysis
The statistical analysis was performed using the SPSS
package (SPSS, Chicago, IL, U.S.A.). To evaluate the
differences between groups, we used Student’s t-test for
the determinations presenting a gaussian distribution,
and the Mann–Whitney test for those presenting a
nongaussian distribution, as was the case for elastase
and CRP. P < 0Æ05 was considered statistically sig-
nificant. Measurements are expressed as mean ± SD.
The strength of the association between the parameters
was estimated by the Pearson correlation coefficient. To
draw the graphs we used Microsoft Excel software.
Results
We analysed the results to study the differences
between controls and patients, between mild and
severe psoriasis (IP vs. AP), and to find values of
prognostic significance for worsening of the disease.
We found a significantly higher WBC count in
patients (P < 0Æ001) (Table 1), which was mainly
due to increased neutrophils (P < 0Æ001). A rise in
WBC count was also found in IP and AP, although this
was significant only in AP (P < 0Æ001). Again, in both
groups this rise was mainly due to neutrophils
(P < 0Æ001). Comparing IP vs. AP patients (Table 1),
we found for AP significantly higher total (P < 0Æ001)
and differential WBC count. Figure 1A shows that only
nine (30%) AP patients presented a WBC count higher
than controls (> 9Æ21 · 109 L)1). However, four
(13%) IP (Fig. 1B) and 19 (63%) AP patients showed
a neutrophil count higher than controls
(> 5Æ43 · 109 L)1).
The inflammatory response study is shown in
Table 2. We found significant differences for all param-
eters in patients (P < 0Æ05 for ceruloplasmin and
transferrin; P < 0Æ001 for all others). In IP we found
the same changes, all being significant (P < 0Æ001)
excepting ceruloplasmin, transferrin and TAS. In AP
the enhanced changes reached significantly higher
values, excluding TAS, which was significantly lower.
Comparing IP vs. AP, we observed a significant
enhancement in all parameters, excepting ceruloplas-
min, transferrin and complement protein C3 (Table 2).
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Concerning WBC activation products, Figure 2A
shows that 23 (77%) AP and 14 (47%) IP patients
presented values of lactoferrin higher than controls
(> 240Æ1 lg L)1). For elastase (Fig. 2B), a value higher
than in controls (> 82Æ4 lg L)1) was observed in 57
(95%) patients. Considering only patients, 21 (70%) AP
patients presented values higher than IP patients
(> 142Æ3 lg L)1). The TBA evaluation, an indirect
marker of ROS generation, showed (Fig. 2C) that all
patients presented lipid peroxidation values higher
than controls (> 2Æ92 lmol L)1).
Some inflammatory markers showed noteworthy
differences (Fig. 3). In 29 (43%) patients we found
fibrinogen levels higher than in controls
(> 339Æ0 mg dL)1) (Fig. 3A), 21 (70%) of them being
AP patients. In 32 (53%) patients, the ESR (Fig. 3B)
presented higher values than controls (> 23Æ0 mm in
the first hour), 25 (80%) of them being AP patients. For
haptoglobin (Fig. 3C), we found that 58 patients (97%)
presented values higher than in controls
(> 188Æ7 mg dL)1). The most striking differences found
between controls, IP and AP patients were in CRP
(Fig. 3D). The 30 IP patients (100%) presented values
higher than controls (> 0Æ36 mg L)1) and values lower
than those shown by the 30 AP patients (100%)
(< 1Æ04 mg L)1).
Concerning the inhibitors of WBC activation prod-
ucts (Fig. 4), we found that 15 AP patients (50%) and
one IP patient presented a TAS value lower than in
controls (< 1Æ27 mmol L)1) (Fig. 4A). For a1-antitryp-
sin (Fig. 4B), we found that 40 patients (67%) presented
a value higher than in controls (> 163Æ4 mg dL)1), 24
(60%) of these being AP patients. For a2-macroglobulin
(Fig. 4C), 39 patients (65%) presented a value higher
than in controls (> 228Æ4 mg dL)1), 26 (87%) of these
being AP patients.
The ratios between elastase and its inhibitors
(Table 3) showed a significant imbalance in patients
in general (P < 0Æ001), as well as in IP and AP patients
separately (P < 0Æ001), when compared with controls.
IP vs. AP showed a significant rise in these ratios
(P < 0Æ001). The individual results (Fig. 5) showed
that 36 patients (60%) presented an elastase ⁄ a2-
macroglobulin ratio higher than in controls (> 0Æ50)
Table 1. Total and differential white blood cell (WBC) count (mean ± SD) for controls and psoriasis patients
C
(n ¼ 40)
IP + AP
(n ¼ 60)
P-value
(IP + AP) ⁄ C
IP
(n ¼ 30)
P-value
IP ⁄ C
AP
(n ¼ 30)
P-value
AP ⁄ C
P-value
IP ⁄ AP
WBC 6Æ69 ± 1Æ30 7Æ72 ± 1Æ52 < 0Æ001 6Æ99 ± 1Æ31 NS 8Æ46 ± 1Æ37 < 0Æ001 < 0Æ001
Neutrophils 3Æ93 ± 0Æ77 5Æ23 ± 1Æ03 < 0Æ001 4Æ66 ± 0Æ83 < 0Æ001 5Æ81 ± 0Æ89 < 0Æ001 < 0Æ001
Lymphocytes 2Æ32 ± 0Æ45 2Æ58 ± 0Æ49 < 0Æ01 2Æ39 ± 0Æ44 NS 2Æ78 ± 0Æ47 < 0Æ001 < 0Æ01
Monocytes 0Æ24 ± 0Æ05 0Æ21 ± 0Æ05 < 0Æ01 0Æ19 ± 0Æ03 < 0Æ001 0Æ23 ± 0Æ05 NS < 0Æ01
WBCs, neutrophils, lymphocytes, monocytes (· 109 L)1); C, control; IP, inactive psoriasis; AP, active psoriasis; NS, not significant.
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Figure 1. Total white blood cell (WBC) count (A) and neutrophil count (B) in the 40 controls (h), in the 30 patients with inactive psoriasis
(IP, n) and in the 30 patients with active psoriasis (AP, s). The control values are under the line (- - -).
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(Fig. 5A); in 16 (53%) AP patients that ratio was
higher than in IP patients (> 0Æ75). For elastase ⁄ a1-
antitrypsin (Fig. 5B), we found in 52 (87%) patients a
value higher than in controls (> 0Æ60); 21 (70%) AP
patients presented a value higher than in IP patients
(> 0Æ87). Two groups were clearly defined for TBA/TAS
ratio (Fig. 5C), as all patients presented a value higher
than controls (> 1Æ97); moreover, we found that 18
(60%) AP patients presented a value higher than in IP
patients (> 5Æ22).
As markers of neutrophil function ⁄ activation, we
evaluated the values of elastase and lactoferrin per
neutrophil (Table 3). We found significantly higher
values in patients (P < 0Æ001, elastase ⁄ neutrophil;
P < 0Æ01, lactoferrin ⁄ neutrophil). In IP and AP
patients both ratios were significantly higher than in
controls; the rise in AP was smaller than in IP for
lactoferrin ⁄ neutrophil. Comparing IP vs. AP patients, a
significantly higher value was found for elastase ⁄ neu-
trophil (P < 0Æ001), but not for lactoferrin ⁄ neutrophil.
We observed (Fig. 6A) that all AP patients and
15 (50%) IP patients presented an elastase ⁄ neutrophil
value higher than in controls (> 22Æ6); in addition, 20
(67%) AP patients presented a value higher than in IP
patients (> 33Æ8). For lactoferrin ⁄ neutrophil no clear
risk values could be established (Fig. 6B).
We also evaluated the correlations between all
studied parameters (data not shown). We found for
elastase more numerous and more highly significant
correlations (Table 4). Elastase showed significant cor-
relations with almost all the parameters studied.
Discussion
Psoriasis is a common and recurrent skin disorder,
characterized by marked inflammatory changes in the
epidermis and dermis. The histopathological study of
active psoriasis lesions has revealed infiltration of
WBCs, in particular of neutrophils. In the present
study, we found a significantly higher WBC count
(Table 1) in patients, resulting from an increased
neutrophil number. In IP patients only a significant
rise in neutrophils was observed. In AP patients both
total WBC and neutrophils were significantly increased.
Comparing IP vs. AP, we found that AP patients
presented significantly higher values of WBC and of
neutrophils.
An inflammatory response may last for minutes,
hours or days, or it may turn into a chronic balanced
process, or into a severe one. In the case of psoriasis,
it may stay balanced or, unexpectedly, it may grow
worse. We found that psoriasis was actually associ-
ated with inflammation (Table 2), as shown by the
significantly higher levels of the inflammatory mark-
ers. In IP patients, these markers were significantly
lower than in AP patients. Psoriasis presented as an
inflammatory condition, and its worsening seemed to
be linked to an enhanced or uncontrolled inflamma-
tory response.
The inflammatory response, by generating chemo-
tactic substances, triggers the mobilization and activa-
tion of the inflammatory cells,1,8 namely the
neutrophils, which may play a crucial role in the
Table 2. Inflammatory markers, products of neutrophil activation and of their inhibitors (mean ± SD) for controls and psoriasis patients
C
(n ¼ 40)
IP + AP
(n ¼ 60)
P-value
(IP + AP) ⁄ C
IP
(n ¼ 30)
P-value
IP ⁄ C
AP
(n ¼ 30)
P-value
AP ⁄ C
P-value
IP ⁄ AP
Lactoferrin 146Æ4 ± 54Æ3 241Æ0 ± 76Æ7 < 0Æ001 219Æ4 ± 68Æ0 < 0Æ001 262Æ6 ± 79Æ9 < 0Æ001 < 0Æ05
TBA 1Æ86 ± 0Æ41 5Æ97 ± 1Æ23 < 0Æ001 5Æ23 ± 1Æ07 < 0Æ001 6Æ72 ± 0Æ89 < 0Æ001 < 0Æ001
Ceruloplasmin 42Æ4 ± 10Æ7 47Æ2 ± 9Æ1 < 0Æ05 45Æ2 ± 9Æ2 NS 49Æ2 ± 8Æ7 < 0Æ01 NS
Transferrin 204Æ0 ± 24Æ7 215Æ6 ± 20Æ3 < 0Æ05 212Æ8 ± 15Æ1 NS 218Æ5 ± 24Æ4 < 0Æ05 NS
TAS 1Æ60 ± 0Æ18 1Æ39 ± 0Æ27 < 0Æ001 1Æ54 ± 0Æ20 NS 1Æ25 ± 0Æ25 < 0Æ001 < 0Æ001
Elastase 54Æ8 ± 16Æ3 155Æ5 ± 69Æ7 < 0Æ001 105Æ2 ± 20Æ9 < 0Æ001 205Æ9 ± 64Æ9 < 0Æ001 < 0Æ001
a1-antitrypsin 139Æ8 ± 17Æ0 170Æ0 ± 20Æ2 < 0Æ001 162Æ3 ± 19Æ3 < 0Æ001 177Æ8 ± 18Æ4 < 0Æ001 < 0Æ01
a2-macroglobulin 186Æ1 ± 27Æ1 242Æ1 ± 38Æ1 < 0Æ001 220Æ1 ± 34Æ4 < 0Æ001 264Æ2 ± 27Æ6 < 0Æ001 < 0Æ001
Fibrinogen 290Æ6 ± 30Æ5 344Æ7 ± 55Æ5 < 0Æ001 321Æ7 ± 36Æ2 < 0Æ001 367Æ6 ± 62Æ2 < 0Æ001 < 0Æ01
ESR 9Æ6 ± 6Æ2 24Æ3 ± 9Æ4 < 0Æ001 18Æ3 ± 7Æ5 < 0Æ001 30Æ2 ± 7Æ1 < 0Æ001 < 0Æ001
CRP 0Æ31 ± 0Æ02 0Æ90 ± 0Æ27 < 0Æ001 0Æ63 ± 0Æ03 < 0Æ001 1Æ16 ± 0Æ07 < 0Æ001 < 0Æ001
Haptoglobin 137Æ0 ± 17Æ7 224Æ2 ± 22Æ2 < 0Æ001 210Æ6 ± 17Æ5 < 0Æ001 237Æ8 ± 17Æ7 < 0Æ001 < 0Æ001
C3 97Æ9 ± 12Æ5 116Æ1 ± 15Æ9 < 0Æ001 112Æ1 ± 17Æ8 < 0Æ001 120Æ0 ± 12Æ7 < 0Æ001 NS
C4 21Æ2 ± 4Æ1 30Æ0 ± 5Æ6 < 0Æ001 26Æ9 ± 4Æ9 < 0Æ001 33Æ2 ± 4Æ3 < 0Æ001 < 0Æ001
Lactoferrin (lg L)1); TBA, thiobarbituric acid (lmol L)1); ceruloplasmin (mg dL)1); transferrin (mg dL)1); TAS, total plasma antioxidant capacity
(mmol L)1); elastase (lg L)1); a1-antitrypsin (mg dL
)1); a2-macroglobulin (mg dL
)1); fibrinogen (mg dL)1); ESR, erythrocyte sedimentation rate
(mm in the first hour); CRP, C-reactive protein (mg dL)1); haptoglobin (mg dL)1); C3 and C4 (mg dL)1); C, control; IP, inactive psoriasis; AP,
active psoriasis; NS, not significant.
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clinical evolution of psoriasis. Their activation includes
the release of the granule constituents13 and a
metabolic burst, producing ROS.19 The increase in
neutrophils in psoriasis seems to be linked to their
activation, considering the observed rise in elastase
and lactoferrin in psoriasis patients (Table 2). In IP,
elastase was double the control value, and in AP it was
almost four times that value. The rise in lactoferrin was
less dramatic, being 1Æ5-fold higher in IP and twofold
higher in AP. The plasma levels of elastase and
lactoferrin should be influenced by the size of the
neutrophil pool, and by its functional activity, shown
by secretion of granule contents. The values of elastase
and lactoferrin per neutrophil were therefore calculated
for comparison of neutrophil number and neutrophil
activation between patients and controls (Table 3). We
found that the degranulation of the primary granules
was stimulated in patients, as shown by a twofold
increase in elastase ⁄ neutrophil. In AP, neutrophils
seem to be hyperstimulated, as this ratio was almost
1Æ5-fold higher than in IP. A stimulated granulocyto-
poiesis is usually associated with immature circulating
neutrophils displaying an increased volume of elastase-
containing granules.20,21 Hence, the observed rise in
elastase ⁄ neutrophil may also reflect this change. The
degranulation of the granules containing lactoferrin
was also stimulated in patients, although to a lesser
extent. Lactoferrin ⁄ neutrophil was higher in IP than in
AP patients, although not significantly. High plasma
levels of lactoferrin in psoriasis were reported by
others.12,22 However, none reported the values accord-
ing to the severity of the disease and to neutrophil
count. The biological function of high plasma levels of
lactoferrin from neutrophils is still incompletely under-
stood.12 It is synthesized by granulocyte precursors
and is stored in the specific granules, available for the
response to infection and inflammation. It may act as a
defence against ROS injury in its iron-free state, by
complexing free iron, and as an enhancer of ROS
production in its iron-loaded state, by providing
catalytic iron.12 Lactoferrin may also promote neutro-
phil adhesion and migration, representing a negative
feedback modulator to prevent recruitment and acti-
vation of WBCs in inflammatory sites, by regulating
cytokine release from mononuclear cells.12,23 The
lower value of lactoferrin ⁄ neutrophil in AP than in
IP may result from a reduced degranulation or from a
reduced lactoferrin content of specific granules. This
could reflect the failure of the feedback mechanism of
lactoferrin to control the enhanced inflammation.
Neutrophil granule subsets are mobilized under a
specific order. Differences in degranulation content
are due to quantitative differences (content or
degranulation rate), and not to differences in the
machinery controlling exocytosis of each granule
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Figure 2. Plasma lactoferrin (A), elastase (B) and lipid peroxide
(TBA, thiobarbituric acid) (C) levels in the 40 controls (h), in the 30
patients with inactive psoriasis (IP, n) and in the 30 patients with
active psoriasis (AP, s). The control values are under the line (- - -);
the values in IP patients are under the line (- Æ Æ -).
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subset.8,13 The different changes observed in ela-
stase ⁄ neutrophil and lactoferrin ⁄ neutrophil may re-
sult from a different mobilization rate of the granule
subsets and ⁄ or from changes in their content. The
reduction in lactoferrin content and ⁄ or in its secre-
tion may represent the failure of the physiological
mechanism to control the inflammatory response, and
it also suggests the ability of neutrophils to interact
with their environment.
The production of ROS was indirectly assessed by the
lipid peroxidation levels (Table 2). We found a threefold
higher value in patients, strengthening the previous
results suggesting neutrophil activation. We also found
that lipid peroxidation was significantly higher in AP
patients than in IP patients.
Lactoferrin, ceruloplasmin and transferrin, all iron-
linking proteins, were higher in AP than in IP;
however, those levels may not avoid the development
of the Fenton reaction, as suggested by the striking
rise in lipid peroxidation, and the clear reduction in
antioxidant defences observed in AP, when compared
with IP.
The release of neutrophil activation products has to
be counterbalanced by well-defined endogenous
systems, to reduce or to avoid the enhancement of
inflammation. We found in patients (Table 2) a signi-
ficant reduction in TAS and an upregulation of
a1-antitrypsin and a2-macroglobulin needed to reduce
the deleterious effects of granular proteases such as
elastase. The rise in lipid peroxides was not followed by
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Figure 3. Levels of the inflammatory markers fibrinogen (A), erythrocyte sedimentation rate (ESR, B), haptoglobin (C) and C-reactive protein
(CRP, D) in the 40 controls (h), in the 30 patients with inactive psoriasis (IP, n) and in the 30 patients with active psoriasis (AP, s). The control
values are under the line (- - -); the values in IP patients are under the line (- Æ Æ -); the values in AP patients are above the line (- - -).
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a similar change in TAS, suggesting the development of
oxidative stress. In IP, TAS was similar to control
values, but a significant reduction was found in AP,
suggesting its depletion.
For a more accurate study of the oxidative and
proteolytic stress in patients, we evaluated the
balance between elastase and their inhibitors, as well
as between lipid peroxidation and total antioxidant
defences (Table 3). We found significant imbalances
(more than twofold the control value), showing the
development of oxidative and proteolytic stress. In
AP, these ratios were almost twofold higher than
in IP.
An imbalance in the protease–antiprotease system,
with uncontrolled proteolysis by elastase, was proposed
to underlie degenerative and degradative disorders.15
Elastase has been found in psoriatic lesions5 and its
activity was associated with scaling and inflammatory
activity.6,24 The imbalances we observed in patients,
between elastase and its inhibitors, suggest that it may
be seriously involved in spreading of the lesions.
Strengthening this, the correlations between all the
studied parameters (data not shown) showed for
elastase more numerous and more highly significant
correlations (Table 4). Hence, besides its crucial role in
the worsening of psoriasis, it may provide a marker for
monitoring the disease.
We may assume that in IP there is a continuous
inflammatory process, underlying a sustained neutro-
phil activation and an oxidative and proteolytic stress.
Suddenly, this apparently controlled form of psoriasis
may turn into a severe form. We considered that it was
important to analyse the results and to search for
values of risk for worsening of psoriasis (Figs 1–6). We
found that neutrophil count was more meaningful
than WBC count (Fig. 1), as only in 30% of AP patients
was the WBC count higher than in controls, whereas
63% of AP patients (and 13% of IP patients) showed a
neutrophil count higher than in controls. Concerning
neutrophil activation products (Fig. 2), we propose
TBA as a marker for psoriasis, as all patients showed a
value above the controls. Elastase also may provide a
marker for psoriasis and for its worsening, as 95% of
patients showed a value above the controls, and in
70% of AP patients the values were beyond the values
in IP patients.
Among inflammatory markers (Fig. 3), haptoglobin
and CRP appeared as markers for psoriasis, as 97% and
100% of patients, respectively, showed values higher
than in controls. However, only CRP seems to provide a
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Figure 5. Balance between leucocyte activation products and their
inhibitors elastase ⁄ a2-macroglobulin (A), elastase ⁄ a1-antitrypsin
(B) and thiobarbituric acid ⁄ total plasma antioxidant capacity
(TBA ⁄ TAS, C) in the 40 controls (h), in the 30 patients with inactive
psoriasis (IP, n) and in the 30 patients with active psoriasis (AP, s).
The control ratios are under the line (- - -); the values in IP patients
are under the line (- Æ Æ -).
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marker for worsening of psoriasis, as all AP patients
showed CRP values above those in IP patients.
Once elastase was identified as a marker for
worsening of psoriasis, it was reasonable to expect
a1-antitrypsin and a2-macroglobulin to be similar
markers. However, they appeared only as markers for
psoriasis, rather than its worsening (Fig. 4), suggesting
an imbalance between elastase and its inhibitors.
Indeed, their ratios (Fig. 5) were found to be higher
than in controls in most cases (60% for elastase ⁄ a2-
macroglobulin; 87% for elastase ⁄ a1-antitrypsin; 100%
for TBA ⁄ TAS). These ratios seem also to provide
markers for worsening of psoriasis, as most AP
patients showed values higher than in IP patients
(53% for elastase ⁄ a2-macroglobulin; 70% for elastase/
a1-antitrypsin; 60% for TBA ⁄ TAS).
Neutrophil function, as given by elastase ⁄ neutrophil,
seems to be a marker for psoriasis, as all AP and half of
IP patients showed a value higher than in controls; it
seems also to be a marker for worsening of psoriasis, as
67% of AP patients showed a value beyond the highest
value in IP.
Further studies are needed to strengthen the
prognostic significance of the proposed markers for
Table 4. Correlation of elastase with the
other studied parameters for psoriasis patients
Elastase IP + AP IP AP
WBC 0Æ617; P < 0Æ001 NS 0Æ589; P < 0Æ001
Neutrophils 0Æ799; P < 0Æ001 0Æ457; P < 0Æ001 0Æ847; P < 0Æ001
Lactoferrin 0Æ616; P < 0Æ001 0Æ391; P < 0Æ001 0Æ752; P < 0Æ001
a1-antitripsin NS 0Æ653; P < 0Æ001 0Æ789; P < 0Æ01
a2-macroglobulin 0Æ573; P < 0Æ001 0Æ219; P < 0Æ001 0Æ357; P < 0Æ001
TBA 0Æ418; P < 0Æ001 NS NS
Ceruloplasmin 0Æ502; P < 0Æ001 0Æ535; P < 0Æ001 0Æ595; P < 0Æ001
Transferrin NS NS NS
TAS NS NS NS
Fibrinogen 0Æ760; P < 0Æ001 0Æ472; P < 0Æ001 0Æ803; P < 0Æ001
ESR 0Æ655; P < 0Æ001 0Æ290; P < 0Æ001 0Æ450; P < 0Æ001
CRP 0Æ795; P < 0Æ001 0Æ350; P < 0Æ001 0Æ623; P < 0Æ001
Haptoglobin 0Æ669; P < 0Æ001 0Æ241; P < 0Æ001 0Æ526; P < 0Æ01
C3 0Æ516; P < 0Æ001 0Æ560; P < 0Æ05 0Æ657; P < 0Æ001
C4 0Æ702; P < 0Æ001 0Æ471; P < 0Æ001 0Æ643; P < 0Æ001
WBC, White blood cells; TBA, thiobarbituric acid; TAS, total plasma antioxidant capacity; ESR,
erythrocyte sedimentation rate; CRP, C-reactive protein; IP, inactive psoriasis; AP, active psor-
iasis; NS, not significant.
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Figure 6. Neutrophil function as measured by the ratios elastase ⁄ neutrophil (A) and lactoferrin ⁄ neutrophil (B) in the 40 controls (h), in the 30
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worsening of psoriasis (elastase > 142Æ3 lg L)1; CRP
> 0Æ69 mg dL)1; elastase ⁄ a2-macroglobulin > 0Æ75; el-
astase ⁄ a1-antitrypsin > 0Æ87; TBA ⁄ TAS > 5Æ22; ela-
stase ⁄ neutrophil > 33Æ8). We believe they could be
useful in the prognosis of psoriasis, by traducing in
advance its worsening. Clinicians would be able to
initiate an adequate therapy earlier, avoiding or min-
imizing the worsening of psoriasis. Moreover, the
markers could contribute to reducing the psychological
impact of psoriasis, which is as debilitating as the
spreading of the lesions.25 They could also be used to
monitor therapy, by giving information about its
success. It would be of particular interest if they could
give that information before visualization of remission of
skin lesions, avoiding unnecessary overtreatment, or
even unnecessary changes to a more aggressive therapy.
In summary, our data show psoriasis to be an
inflammatory condition in which neutrophils seem to
play a crucial role by contributing to the development
of oxidative and proteolytic stress. The worsening of
psoriasis seems to be linked to an imbalance between
neutrophil activation products and their inhibitors.
We propose that the insufficiency of the antioxidant
defences and of the antiprotease system to face the
enhanced release of neutrophil activation products
may lead to an uncontrolled inflammatory process.
Several conditions may trigger the enhancement of
psoriasis, such as infections,26 skin traumas and
stress conditions.4 All of them must trigger in IP an
additional inflammatory stimulus, which may disrupt
the fragile balance between the inflammatory prod-
ucts and the counterbalancing endogenous systems.
Epidermal hyperproliferation and inflammation are
the main features in psoriasis. In our study we tried to
characterize further the inflammatory response in IP
and AP, in order to find potential prognostic markers
of worsening or improvement of psoriasis, by estab-
lishing the differences between both forms of psoriasis.
We wonder if the observed changes are a cause or an
effect of the disease, or both. In IP the changes are
probably an effect of the disease; however, when an
additional inflammatory response is needed, it may be
the cause for worsening of psoriasis by the imbalance
caused, but in addition, ultimately, also an effect of
the disease.
A great deal of research is underway on psoriasis and
on new therapies.15,27–31 Our data, by stressing the role
of neutrophil activation products and of their inhibitors,
the antioxidant defences and the antiprotease system,
support therapeutic research in these areas.
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